HIV-1 Latency: Coloring hidden viruses

An improved dual-color reporter reveals how the fate of latent HIV-1 depends on where it integrates in the human genome.
  1. Marina Lusic  Is a corresponding author
  1. University of Heidelberg, Germany

Current antiviral therapies can suppress HIV-1 in the bloodstream to almost undetectable levels. Yet, if this therapy is interrupted, the number of viruses can start to increase again and go on to conquer the defenses of the immune system. This occurs when viruses that are in a dormant, or ‘latent’, state become reactivated. Characterized by limited gene expression and zero viral replication, latent viruses remain hidden from the immune system and are not affected by antiviral drugs, unless they are reactivated.

Latent HIV-1 is integrated within the genomes of immune cells, mainly resting CD4+ T cells and, to a lesser extent, macrophages (Churchill et al., 2016). Cells that represent latent reservoirs of HIV-1 are usually very rare and difficult to separate from the neighboring non-infected cells. This means that few of these cells have been available for study, which in turn has severely hampered our understanding of the mechanisms behind viral reactivation. Now, in eLife, Eric Verdin and colleagues – including Emilie Battivelli as first author – report on an improved ‘dual-color virus’ that allows cells harboring hidden latent viruses to be identified and isolated (Battivelli et al., 2018).

Over the past decade, much HIV-1 research has looked for ways to eliminate the latent viral reservoirs by first using pharmacological molecules to reverse latency in a ‘shock and kill’ approach (Deeks et al., 2012). The increased levels of gene expression in the reactivated viruses should lead to viral antigens being presented on the surface of latently infected cells. This in turn would allow the immune system to find and clear these cells and, typically, make the viruses susceptible to antiviral therapy again (Churchill et al., 2016; Margolis et al., 2016). However, this shock and kill approach only had limited success, mostly because it could not completely reactivate the virus from its latent state.

To develop more effective approaches for reactivating viruses we first need better ways to obtain resting CD4+ T cells that contain latent viruses in order to study them. So-called dual-color viruses – which have two fluorescent reporters under the control of different promoters – can help with this (Calvanese et al., 2013; Chavez et al., 2015). With the original version of this reporter virus (called HIVDuoFluoI), infected cells would glow red, making them clearly distinct from non-infected cells. If the integrated virus was active, a green fluorescent protein was also produced and the cells appeared both red and green. Latently infected cells (i.e., those with integrated yet inactive virus) could thus easily be distinguished by their pure red color.

Although this is how the tool should have worked in theory, there was room for improvement. Some of the sequences used in HIVDuoFluoI could readily recombine, meaning this dual-color virus was prone to losing its reporters, which made it impossible to track reliably. Battivelli et al. – who are based at the Gladstone Institutes, UCSF, the Buck Institute for Research on Aging and other institutes across the United States, Sweden and Brazil – overcame this specific issue by changing some sequences to create an improved dual-color virus. The new version, called HIVGKO, contains a different green reporter (a codon-switched eGFP) under the control of the HIV-1 specific promoter. It also has an unrelated orange, rather than red, fluorescent protein (mutated Kusubira Orange) under the control of the constitutive promoter.

HIVGKO allowed Battivelli et al. to examine the integration sites of latent viruses that could be reactivated and to understand how the genetic material around those sites was packaged in the nucleus (also known as the ‘chromatin context’). They could then compare these results to those from the viruses that could not be reactivated. Battivelli et al. designed their study to compare the potency of several drugs that were known to reactivate latent reservoirs via different mechanisms (Barton et al., 2016; Conrad et al., 2017; Mehla et al., 2010).

All the drugs tested showed limited reactivation unless they were used in combination. Battivelli et al. then mapped HIV-1 insertions from three different groups of infected cells. The first group contained cells with an integrated virus that was actively producing copies of itself – or productively infected cells (Figure 1). The second and third groups were non-reactivated and reactivated latently infected cells, respectively. Battivelli et al. further defined the chromatin context of the integrated viruses, and found that viruses within both productively infected cells and reactivated latently infected cells reside mainly in the active chromatin of transcribed genes and enhancers (Chen et al., 2017). Their analysis showed that viruses found in non-reactivated latently infected cells are detected within large genomic regions that interact with the dense meshwork of proteins that line the inner surface of the nucleus envelope, the nuclear lamina (Guelen et al., 2008; Marini et al., 2015). Some repressed viruses that could be reactivated were also found in the same region in reactivated latently infected cells.

Scanning electron micrograph of an HIV-infected T cell.

The human immunodeficiency virus (HIV; yellow) buds from the surface of a productively infected T cell (red).

IMAGE CREDIT: NIAID.

The fact that all the drugs tested only partially reactivated a small portion of latent viruses implies that latent reservoirs of HIV-1 are heterogeneous in nature. This finding also clearly points to the fact that transcriptional repression of HIV-1 can be influenced by the context of where it integrates in the host cell’s genome. As this is a first study where this context could be connected directly to the fate of HIV-1 infection, it becomes clear that there are many lessons to be learned about how HIV-1 explores the human genome (especially in T cells) to integrate and persist.

References

Article and author information

Author details

  1. Marina Lusic

    Marina Lusic is at the Center for Integrative Infectious Disease Research, University of Heidelberg, Heidelberg, Germany

    For correspondence
    marina.lusic@med.uni-heidelberg.de
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0120-3569

Publication history

  1. Version of Record published: May 29, 2018 (version 1)

Copyright

© 2018, Lusic

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,568
    Page views
  • 152
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marina Lusic
(2018)
HIV-1 Latency: Coloring hidden viruses
eLife 7:e37732.
https://doi.org/10.7554/eLife.37732

Further reading

    1. Microbiology and Infectious Disease
    Cecile Berne, Sebastien Zappa, Yves V Brun
    Research Article

    In their natural environment, most bacteria preferentially live as complex surface-attached multicellular colonies called biofilms. Biofilms begin with a few cells adhering to a surface, where they multiply to form a mature colony. When conditions deteriorate, cells can leave the biofilm. This dispersion is thought to be an important process that modifies the overall biofilm architecture and that promotes colonization of new environments. In Caulobacter crescentus biofilms, extracellular DNA (eDNA) is released upon cell death and prevents newborn cells from joining the established biofilm. Thus, eDNA promotes the dispersal of newborn cells and the subsequent colonization of new environments. These observations suggest that eDNA is a cue for sensing detrimental environmental conditions in the biofilm. Here we show that the toxin-antitoxin system (TAS) ParDE4 stimulates cell death in areas of a biofilm with decreased O2 availability. In conditions where O2 availability is low, eDNA concentration is correlated with cell death. Cell dispersal away from biofilms is decreased when parDE4 is deleted, probably due to the lower local eDNA concentration. Expression of parDE4 is positively regulated by O2 and the expression of this operon is decreased in biofilms where O2 availability is low. Thus, a programmed cell death mechanism using an O2-regulated TAS stimulates dispersal away from areas of a biofilm with decreased O2 availability and favors colonization of a new, more hospitable environment.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    James A Watson, Robert J Commons ... Nicholas J White
    Research Article Updated

    Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual data from 1102 patients and 72 healthy volunteers studied in the pre-registration trials. We show that tafenoquine dose is the primary determinant of efficacy. Under an Emax model, we estimate the currently recommended 300 mg dose in a 60 kg adult (5 mg/kg) results in 70% of the maximal obtainable hypnozoiticidal effect. Increasing the dose to 7.5 mg/kg (i.e. 450 mg) would result in 90% reduction in the risk of P. vivax recurrence. After adjustment for dose, the tafenoquine terminal elimination half-life, and day 7 methaemoglobin concentration, but not the parent compound exposure, were also associated with recurrence. These results suggest that the production of oxidative metabolites is central to tafenoquine’s hypnozoiticidal efficacy. Clinical trials of higher tafenoquine doses are needed to characterise their efficacy, safety and tolerability.